Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second-line Advanced Therapy in Crohn's Disease: Real-life Effectiveness and Resolution of First-line Suboptimal Control Indicators (CROHNOS - CROHN Therapy Observational Study)

NCT07073079 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07073079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07073079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second-line Advanced Therapy in Crohn's Disease: Real-life Effectiveness and Resolution of First-line Suboptimal Control Indicators (CROHNOS - CROHN Therapy Observational Study)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
July 14, 2025
Completion date
December 31, 2027
Enrollment
250 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease